Recordati (REC) Q2 2024 earnings summary

Executive summary

• Net revenue for H1 2024 reached €1,185.7 million, up 13.5% year-over-year, driven by strong growth in both Specialty & Primary Care and Rare Diseases segments, with robust momentum across all business units and geographies.

• EBITDA rose 11.5% to €452.9 million, with a margin of 38.2%, reflecting operating leverage despite a diluted gross margin from product mix.

• Adjusted net income increased 4.7% to €301.0 million, while reported net income declined 1.0% to €225.4 million due to higher tax rates and financial expenses.

• Free cash flow was €256.6 million, slightly down due to higher interest and tax payments, with leverage just below 1.8x EBITDA pro-forma.

• 2024 financial targets were revised upward, reflecting continued business strength and positive outlook.

Financial highlights

• Net revenue grew 13.5% year-over-year to €1,185.7 million; like-for-like growth at constant exchange rates was 10.2%.

• EBITDA reached €452.9 million (+11.5%), with a margin of 38.2%.

• Adjusted net income was €301.0 million (+4.7%), while net income was €225.4 million (-1.0%).

• Gross profit margin declined to 67.6% (from 70.1%) due to product/country mix and new product consolidation.

• Free cash flow totaled €256.6 million, a decrease of €5.1 million year-over-year.

Outlook and guidance

• 2024 net revenue guidance raised to €2,300–2,340 million (previously €2,260–2,320 million), with double-digit top-line growth expected.

• 2024 EBITDA guidance increased to €845–865 million (was €830–860 million), with a margin of ~37%.

• Adjusted net income guidance for 2024 now €560–580 million (was €550–570 million), margin ~24.5%.

• 2025 targets reaffirmed: revenue over €2.4 billion and EBITDA margin of ~37%.

• SPC expected to deliver mid-single digit organic growth at CER; RRD to maintain strong double-digit growth.